z-logo
open-access-imgOpen Access
New antigens involved in membranous nephropathy beyond phospholipase A2 receptor
Author(s) -
Maurizio Salvadori,
Aris Tsalouchos
Publication year - 2022
Publication title -
world journal of nephrology
Language(s) - English
Resource type - Journals
ISSN - 2220-6124
DOI - 10.5527/wjn.v11.i4.115
Subject(s) - membranous nephropathy , antigen , antibody , immunology , medicine , glomerulonephritis , western blot , pathology , biology , kidney , biochemistry , gene
When the physiopathology of membranous nephropathy was first described, almost 30% of cases were recognized to be secondary to well-known diseases such as autoimmune diseases, tumors or infections. The remaining 70% cases were called primary membranous nephropathy as the exact mechanism or pathogenic factor involved was unknown. The discovery of the M type phospholipase A2 receptor and thrombospondin type 1 domain containing 7A as causative antigens in these "so called" primary membranous nephropathies provided new insights into the effective causes of a large proportion of these cases. Novel techniques such as laser microdissection and tandem mass spectrometry as well as immunochemistry with antibodies directed against novel proteins allowed the confirmation of new involved antigens. Finally, using confocal microscopy to localize these new antigens and immunoglobulin G and Western blot analysis of serum samples, these new antigens were detected on the glomerular membrane, and the related antibodies were detected in serum samples. The same antigens have been recognized in some cases of secondary membranous disease due to autoimmune diseases, tumors and infections. This has allowed examination of the relationship between antigens in primary membranous nephropathy and their presence in some secondary nephropathies. The aim of this study is to describe the characteristics of the new antigens discovered and their association with other diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here